Memorial for a radiopharmaceutical – Azedra or No carrier added [131I]-MIBG
Sign Up to like & getrecommendations! Published in 2025 at "Canadian Journal of Chemistry"
DOI: 10.1139/cjc-2025-0187
Abstract: Azedra is the name given to high specific activity/ high molar activity MIBG (m-[131I]-(iodobenzylguanindinium); iobenguane (131I) produced commercially for the treatment of adrenal carcinoma: neuroblastoma, pheochromocytoma and paraganglioma. Azedra was patented in 2007; human clinical… read more here.
Keywords: radiopharmaceutical azedra; carrier added; azedra carrier; memorial radiopharmaceutical ... See more keywords
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.941832
Abstract: Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific activity and has waste disposal advantages over the first generation… read more here.
Keywords: neuroendocrine tumors; added 177; prrt; treatment ... See more keywords